Abstract
Purpose
Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical efficacy of the bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown.
Methods
We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project).
Results
A total of 5896 STEMI patients who received thrombus aspiration were identified, among which 56.3% received GPI therapy. In a 1-to-1 propensity-score-matched cohort, compared with STEMI patients not treated with GPI, GPI use was associated with a 69% increase in major in-hospital bleeds, with an odds ratio (OR) of 1.69, a 95% confidence interval (CI) of 1.08 to 2.65, and a nonsignificant reduction in ischemic events (OR: 0.61, 95% CI: 0.36 to 1.06), as well as a neutral effect on mortality (OR: 0.93, 95% CI: 0.55 to 1.58). However, among patients aged < 60 years, GPI use was associated with a reduction in ischemic events (OR: 0.27, 95% CI: 0.08 to 0.98), and no significant increase in major bleeds was observed.
Conclusion
In a nationwide registry, routine use of GPI following thrombus aspiration was not associated with reduced in-hospital ischemic events and mortality but at the cost of increased major bleeding. However, for patients aged < 60 years, there may be a potential net benefit.
Similar content being viewed by others
Data Availability
Not applicable.
Code Availability
Not applicable.
References
Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. 2013;34:719–28.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI Focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67:1235–50.
Montalto C, Kotronias RA, Marin F, Terentes-Printzios D, Shanmuganathan M, Emfietzoglou M, Scalamera R, Porto I, Langrish J, Lucking A, et al. Pre-procedural ATI score (age-thrombus burden-index of microcirculatory resistance) predicts long-term clinical outcomes in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Int J Cardiol. 2021;339:1–6.
Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S, Olivecrona GK, Renlund H, Gao P, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135:143–52.
[2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47:766–783.
Chang K, Ahn Y, Lim S, Yang JH, Lee KY, Choo EH, Kim HK, Nam CW, Kim W, Hwang JY, et al. 2021 Korean society of myocardial infarction expert consensus document on revascularization for acute myocardial infarction. Korean Circ J. 2021;51:289–307.
Li YH, Lee CH, Huang WC, Wang YC, Su CH, Sung PH, Chien SC, Hwang JJ. 2020 Focused Update of the 2012 Guidelines of the Taiwan society of cardiology for the management of ST-segment elevation myocardial infarction. Acta Cardiol Sin. 2020;36:285–307.
Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, et al. JCS 2018 Guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–196.
Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121:422–32.
Wu JH, Hao PP, Chen YG, Li RJ. Intracoronary glycoprotein IIb/IIIa inhibitors improve short-term mortality and reinfarction in East Asian patients with ST-segment elevation myocardial infarction after thrombus aspiration: a meta-analysis. Evid Based Complement Alternat Med. 2018;2018:5174714.
Zheng C, Kang J, Yang HM, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Safety and efficacy of glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction in the presence of intracoronary thrombus: an analysis from the grand drug-eluting stent registry. Clin Ther. 2020;42:954-958.e956.
Hao Y, Liu J, Liu J, Smith SC Jr, Huo Y, Fonarow GC, Ma C, Ge J, Taubert KA, Morgan L, et al. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: a national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. 2016;179:107–15.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
Choudry FA, Hamshere SM, Rathod KS, Akhtar MM, Archbold RA, Guttmann OP, Woldman S, Jain AK, Knight CJ, Baumbach A, et al. High thrombus burden in patients With COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76:1168–76.
Jolly SS, Cairns JA, Lavi S, Cantor WJ, Bernat I, Cheema AN, Moreno R, Kedev S, Stankovic G, Rao SV, et al. Thrombus aspiration in patients with high thrombus burden in the TOTAL Trial. J Am Coll Cardiol. 2018;72:1589–96.
Crea F, Camici PG, BaireyMerz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101–11.
Alexopoulos D, Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Makris G, Gizas V, Kassimis G, Davlouros P, Hahalis G. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction. Thromb Res. 2013;131:333–7.
Huang D, Qian J, Liu Z, Xu Y, Zhao X, Qiao Z, Fang W, Jiang L, Hu W, Shen C, et al. Effects of intracoronary pro-urokinase or tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: a multi-center, placebo-controlled, single-blind, randomized clinical trial. Front Cardiovasc Med. 2021;8: 710994.
Mahmoud KD, Zijlstra F. Thrombus aspiration in acute myocardial infarction. Nat Rev Cardiol. 2016;13:418–28.
Zhou SS, Tian F, Chen YD, Wang J, Sun ZJ, Guo J, Jin QH. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. J Geriatr Cardiol. 2015;12:135–42.
Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, et al. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: an analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019;278:217–22.
Velibey Y, Guvenc TS, Demir K, Oz A, Akdeniz E, Guvenc RC, Guzelburc O, Yildiz U, Safak A, Kalenderoglu K, et al. Effects of bailout tirofiban on in-hospital outcomes and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Angiology. 2019;70:431–9.
Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–9.
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–66.
Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011;107:1136–43.
Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2015;36:3238–49.
Acknowledgements
The article was written on behalf of the CCC-ACS project investigators.
Funding
This work was supported by a collaborative program of the American Heart Association and the Chinese Society of Cardiology. The American Heart Association was funded by Pfizer and AstraZeneca for the quality improvement initiative through an independent grant for learning and change. This work was also supported by the National Key R&D Program of China (Nos. 2020YFC2004700, 2020YFC2004706), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-069C), and Tianjin Municipal Science and Technology Commission (19JCQNJC11500).
Author information
Authors and Affiliations
Consortia
Contributions
XZ, QY, and YL conceived and designed the study, supervised the analysis process, interpreted the data, and revised the manuscript. WL and ZL analyzed the data and drafted the manuscript. WL, ZL, TY, GA, HS, HL, XS, ZJ, and LL helped to analyze the data and table and figure generation. YH, JL, and DZ supervised the CCC-ACS project and interpreted the data. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics Approval
The CCC-ACS project was approved by the institutional review board of Beijing Anzhen Hospital, Capital Medical University, with a waiver for informed consent.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A complete list of CCC-ACS investigators is given at the Supplemental Table 11.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liu, W., Li, Z., Yang, T. et al. Association Between Platelet Glycoprotein IIb/IIIa Inhibition and In-Hospital Outcomes in ST-Elevation Myocardial Infarction Patients Treated with Coronary Thrombus Aspiration: Findings from the CCC-ACS Project. Cardiovasc Drugs Ther 38, 315–325 (2024). https://doi.org/10.1007/s10557-022-07398-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-022-07398-w